Last reviewed · How we verify
Low dose topiramate
Low dose topiramate, marketed by the Mario Negri Institute for Pharmacological Research, holds a niche position in the pharmaceutical market with its unique low-dose formulation. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of exclusivity and protection from generic competition. The primary risk is the lack of significant revenue data, which may indicate limited market penetration or sales volume.
At a glance
| Generic name | Low dose topiramate |
|---|---|
| Also known as | Low topiramate |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Use of Driving Tests to Evaluate Patient Performance on Oral Opioids
- New Treatment for Alcohol and Nicotine Dependence (PHASE2, PHASE3)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult (NA)
- Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) (PHASE3)
- Phase IV Study of Qsymia in Obese Patients (PHASE4)
- Topiramate-Phentermine Combinations for Cocaine Dependence (PHASE1)
- Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose topiramate CI brief — competitive landscape report
- Low dose topiramate updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI